Obesity and the risk of cardiometabolic diseases

PL Valenzuela, P Carrera-Bastos… - Nature reviews …, 2023 - nature.com
The prevalence of obesity has reached pandemic proportions, and now approximately 25%
of adults in Westernized countries have obesity. Recognized as a major health concern …

Obesity and cardiovascular disease: a scientific statement from the American Heart Association

TM Powell-Wiley, P Poirier, LE Burke, JP Després… - Circulation, 2021 - Am Heart Assoc
The global obesity epidemic is well established, with increases in obesity prevalence for
most countries since the 1980s. Obesity contributes directly to incident cardiovascular risk …

Obesity in pregnancy

AA Creanga, PM Catalano… - New England Journal of …, 2022 - Mass Medical Soc
Obesity in Pregnancy | New England Journal of Medicine Skip to main content The New
England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology …

[HTML][HTML] Excess body weight: Novel insights into its roles in obesity comorbidities

X Zhang, S Ha, HCH Lau, J Yu - Seminars in cancer biology, 2023 - Elsevier
Excess body weight is a global health problem due to sedentary lifestyle and unhealthy diet,
affecting 2 billion population worldwide. Obesity is a major risk factor for metabolic diseases …

Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications

J Ren, NN Wu, S Wang, JR Sowers… - Physiological …, 2021 - journals.physiology.org
The prevalence of heart failure is on the rise and imposes a major health threat, in part, due
to the rapidly increased prevalence of overweight and obesity. To this point …

Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study

R Nahra, T Wang, KM Gadde, J Oscarsson… - Diabetes …, 2021 - Am Diabetes Assoc
OBJECTIVE Cotadutide, a dual GLP-1 and glucagon receptor agonist, is under development
for nonalcoholic steatohepatitis (NASH) and chronic kidney disease with type 2 diabetes …

Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement

IJ Neeland, R Ross, JP Després… - The lancet Diabetes & …, 2019 - thelancet.com
Findings from epidemiological studies over the past 30 years have shown that visceral
adipose tissue, accurately measured by CT or MRI, is an independent risk marker of …

Causes, consequences, and treatment of metabolically unhealthy fat distribution

N Stefan - The lancet Diabetes & endocrinology, 2020 - thelancet.com
An increase in fat mass is considered to be an important risk factor for the worldwide
increase in type 2 diabetes and cardiovascular disease. However, for a given fat mass, there …

Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome

CR Kahn, G Wang, KY Lee - The Journal of clinical …, 2019 - Am Soc Clin Investig
Over the past decade, great progress has been made in understanding the complexity of
adipose tissue biology and its role in metabolism. This includes new insights into the …

Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies

JA Batsis, DT Villareal - Nature Reviews Endocrinology, 2018 - nature.com
The prevalence of obesity in combination with sarcopenia (the age-related loss of muscle
mass and strength or physical function) is increasing in adults aged 65 years and older. A …